Role of serum toll-like receptors 2 and 4 in non-alcoholic steatohepatitis and liver fibrosis

Journal of Gastroenterology and Hepatology (Australia)

Volumn 30, Issue 7, 2015, Pages 1190-1196

  Cengiz, Mustafa ^a   Ozenirler, Seren ^b   Elbeg, Sehri ^b  

^a ANKARA ONCOLOGY EDUCATION AND RESEARCH HOSPITAL   (Turkey)

^b GAZI UNIVERSITY FACULTY OF MEDICINE   (Turkey)

Author keywords

NASH; Non invasive marker; Toll like receptors

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; BIOLOGICAL MARKER; DOBUTAMINE; TLR2 PROTEIN, HUMAN; TLR4 PROTEIN, HUMAN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SCORING SYSTEM; THROMBOCYTE; BLOOD; FORECASTING; MIDDLE AGED; MOLECULAR GENETICS;

ADULT; AGED; BIOMARKERS; DOBUTAMINE; FORECASTING; HUMANS; LIVER CIRRHOSIS; MIDDLE AGED; MOLECULAR SEQUENCE DATA; NON-ALCOHOLIC FATTY LIVER DISEASE; TOLL-LIKE RECEPTOR 2; TOLL-LIKE RECEPTOR 4;

EID: 84931027253     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.12924     Document Type: Article

References (48)

1. Rafiq N, Younossi ZM. Nonalcoholic fatty liver disease: a practical approach to evaluation and management. Clin. Liver Dis. 2009; 13: 249-266.
2. Brunt EM. Nonalcoholic steatohepatitis: pathologic features and differential diagnosis. Semin. Diagn. Pathol. 2005; 22: 330-338.
3. Sheth SG, Gordon FD, Chopra S. Nonalcoholic steatohepatitis. Ann. Intern. Med. 1997; 126: 137-145.
4. Adams LA, Lymp JF, St Sauver J etal. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005; 129: 113-121.
5. Marrero JA, Fontana RJ, Su GL, Conjeevaram HS, Emick DM, Lok AS. NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology 2002; 36: 1349-1354.
6. Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology 2010; 51: 1820-1832.
7. Sebastiani G, Alberti A. Non invasive fibrosis biomarkers reduce but not substitute the need for liver biopsy. World J. Gastroenterol. 2006; 12: 3682-3694.
8. West J, Card TR. Reduced mortality rates following elective percutaneous liver biopsies. Gastroenterology 2010; 139: 1230-1237.
9. Castera L. Noninvasive methods to assess liver disease in patients with hepatitis B or C. Gastroenterology 2012; 142: 1293-1302.
10. Cengiz M, Ozenirler S, Yucel AA, Yilmaz G. Can serum pin1 level be regarded as an indicative marker of nonalcoholic steatohepatitis and fibrotic stages? Digestion 2014; 90: 35-41.
11. Ozenirler S, Erkan G, Konca Degertekin C etal. The relationship between advanced oxidation protein products (AOPP) and biochemical and histopathological findings in patients with nonalcoholic steatohepatitis. J. Dig. Dis. 2014; 15: 131-136.
12. Cengiz M, Candir BA, Yilmaz G, Akyol G, Ozenirler S. Is increased red cell distribution width an indicating marker of nonalcoholic steatohepatitis and fibrotic stage? World J. Gastroenterol. 2013; 19: 7412-7418.
13. Blancou J. Early methods for the surveillance and control of glanders in Europe. Rev. Sci. Tech. 1994; 13: 545-557.
14. Younossi ZM, Jarrar M, Nugent C etal. A novel diagnostic biomarker panel for obesity-related nonalcoholic steatohepatitis (NASH). Obes. Surg. 2008; 18: 1430-1437.
15. Jagavelu K, Routray C, Shergill U, O'Hara SP, Faubion W, Shah VH. Endothelial cell toll-like receptor 4 regulates fibrosis-associated angiogenesis in the liver. Hepatology 2010; 52: 590-601.
16. Mencin A, Kluwe J, Schwabe RF. Toll-like receptors as targets in chronic liver diseases. Gut 2009; 58: 704-720.
17. Miyake Y, Yamamoto K. Role of gut microbiota in liver diseases. Hepatol. Res. 2013; 43: 139-146.
18. Tsukumo DM, Carvalho-Filho MA, Carvalheira JB etal. Loss-of-function mutation in Toll-like receptor 4 prevents diet-induced obesity and insulin resistance. Diabetes 2007; 56: 1986-1998.
19. Rivera CA, Adegboyega P, van Rooijen N, Tagalicud A, Allman M, Wallace M. Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of non-alcoholic steatohepatitis. J. Hepatol. 2007; 47: 571-579.
20. Spruss A, Kanuri G, Wagnerberger S, Haub S, Bischoff SC, Bergheim I. Toll-like receptor 4 is involved in the development of fructose-induced hepatic steatosis in mice. Hepatology 2009; 50: 1094-1104.
21. Kodama Y, Kisseleva T, Iwaisako K etal. c-Jun N-terminal kinase-1 from hematopoietic cells mediates progression from hepatic steatosis to steatohepatitis and fibrosis in mice. Gastroenterology 2009; 137: 1467-1477.
22. de Almeida IT, Cortez-Pinto H, Fidalgo G, Rodrigues D, Camilo ME. Plasma total and free fatty acids composition in human non-alcoholic steatohepatitis. Clin. Nutr. 2002; 21: 219-223.
23. Schaeffler A, Gross P, Buettner R etal. Fatty acid-induced induction of Toll-like receptor-4/nuclear factor-kappaB pathway in adipocytes links nutritional signalling with innate immunity. Immunology 2009; 126: 233-245.
24. Seki E, De Minicis S, Osterreicher CH etal. TLR4 enhances TGF-beta signaling and hepatic fibrosis. Nat. Med. 2007; 13: 1324-1332.
25. Kim HS, Go H, Akira S, Chung DH. TLR2-mediated production of IL-27 and chemokines by respiratory epithelial cells promotes bleomycin-induced pulmonary fibrosis in mice. J. Immunol. 2011; 187: 4007-4017.
26. Lee IT, Lee CW, Tung WH etal. Cooperation of TLR2 with MyD88, PI3K, and Rac1 in lipoteichoic acid-induced cPLA2/COX-2-dependent airway inflammatory responses. Am. J. Pathol. 2010; 176: 1671-1684.
27. Miura K, Yang L, van Rooijen N, Brenner DA, Ohnishi H, Seki E. Toll-like receptor 2 and palmitic acid cooperatively contribute to the development of nonalcoholic steatohepatitis through inflammasome activation in mice. Hepatology 2013; 57: 577-589.
28. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am. J. Gastroenterol. 1999; 94: 2467-2474.
29. Kleiner DE, Brunt EM, Van Natta M etal. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313-1321.
30. Saadeh S, Cammell G, Carey WD, Younossi Z, Barnes D, Easley K. The role of liver biopsy in chronic hepatitis C. Hepatology 2001; 33: 196-200.
31. Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003; 38: 1449-1457.
32. Marchesini G, Babini M. Nonalcoholic fatty liver disease and the metabolic syndrome. Minerva Cardioangiol. 2006; 54: 229-239.
33. Panchal SK, Brown L. Rodent models for metabolic syndrome research. J. Biomed. Biotechnol. 2011; 2011: 1-14. doi: 10.1155/2011/351982.
34. Kanuri G, Ladurner R, Skibovskaya J etal. Expression of toll-like receptors 1-5 but not TLR 6-10 is elevated in livers of patients with non-alcoholic fatty liver disease. Liver Int. 2015; 35: 562-568.
35. Bataller R, Brenner DA. Liver fibrosis. J. Clin. Invest. 2005; 115: 209-218.
36. Brun P, Castagliuolo I, Pinzani M, Palu G, Martines D. Exposure to bacterial cell wall products triggers an inflammatory phenotype in hepatic stellate cells. Am. J. Physiol. Gastrointest. Liver Physiol. 2005; 289: 571-578.
37. LeBouder E, Rey-Nores JE, Rushmere NK etal. Soluble forms of Toll-like receptor (TLR)2 capable of modulating TLR2 signaling are present in human plasma and breast milk. J. Immunol. 2003; 171: 6680-6689.
38. Iwami KI, Matsuguchi T, Masuda A, Kikhuchi T, Musikacharoen T, Yoshikai Y. Cutting edge: naturally occurring soluble form of mouse Toll-like receptor 4 inhibits lipopolysaccharide signaling. J. Immunol. 2000; 165: 6682-6686.
39. Durieux JJ, Vita N, Popescu O etal. The two soluble forms of the lipopolysaccharide receptor, CD14: characterization and release by normal human monocytes. Eur. J. Immunol. 1994; 24: 2006-2012.
40. Rivera CA, Gaskin L, Allman M etal. Toll-like receptor-2 deficiency enhances non-alcoholic steatohepatitis. BMC Gastroenterol. 2010; 10: 52. doi: 10.1186/1471-230X-10-52.
41. Qian H, Shi J, Fan TT etal. Sophocarpine attenuates liver fibrosis by inhibiting the TLR4 signaling pathway in rats. World J. Gastroenterol. 2014; 20: 1822-1832.
42. Bai T, Lian LH, Wu YL, Wan Y, Nan JX. Thymoquinone attenuates liver fibrosis via PI3K and TLR4 signaling pathways in activated hepatic stellate cells. Int. Immunopharmacol. 2013; 15: 275-281.
43. Miele L, Valenza V, La Torre G etal. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology 2009; 49: 1877-1887.
44. Brun P, Castagliuolo I, Di Leo V etal. Increased intestinal permeability in obese mice: new evidence in the pathogenesis of nonalcoholic steatohepatitis. Am. J. Physiol. Gastrointest. Liver Physiol. 2007; 292: 518-525.
45. Wu WC, Zhao W, Li S. Small intestinal bacteria overgrowth decreases small intestinal motility in the NASH rats. World J. Gastroenterol. 2008; 14: 313-317.
46. Volynets V, Kuper MA, Strahl S etal. Nutrition, intestinal permeability, and blood ethanol levels are altered in patients with nonalcoholic fatty liver disease (NAFLD). Dig. Dis. Sci. 2012; 57: 1932-1941.
47. Roh YS, Seki E. Toll-like receptors in alcoholic liver disease, non-alcoholic steatohepatitis and carcinogenesis. J. Gastroenterol. Hepatol. 2013; 28 (Suppl. 1): 38-42.
48. Vespasiani-Gentilucci U, Carotti S, Perrone G etal. Hepatic toll-like receptor 4 expression is associated with portal inflammation and fibrosis in patients with NAFLD. Liver Int. 2015; 35: 569-581.